A recent large-scale study has highlighted a concerning pattern: two years after stopping GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound), patients faced a 22% higher risk of heart attack, stroke, and death compared to those who continued treatment. These numbers are striking. And beyond cardiology, I believe they carry an important message for anyone dealing with chronic pain or osteoarthritis.
Why GLP-1 drugs matter for patients with joint pain
I have written before about a recent discovery: traces of the GLP-1 hormone, targeted by these medications, were found directly inside the joints of arthritis patients. This suggests that these drugs may not work solely through weight loss, but also by directly reducing local inflammation in the joints.
This new study on cardiovascular risk after stopping treatment reinforces a central idea: the benefits of these medications are real, but they appear to depend on continuous use. Once treatment stops, the protective effects seem to fade relatively quickly.
For patients who take these drugs partly to manage joint inflammation or chronic pain, this is important information to understand.
Inflammation at the heart of the matter
What this study illustrates clearly is the central role of inflammation across conditions that may seem unrelated: heart disease, osteoarthritis, chronic pain. These conditions often share the same underlying biological mechanisms.
In my osteopathic practice, I work precisely at this level: not on isolated symptoms, but on the broader imbalances that keep inflammation going. Poor joint mobility, compensatory posture, a chronically stressed autonomic nervous system: all of these silently feed inflammation over time.
The body does not work in silos. What affects your heart also touches your joints, your nervous system, and your daily pain levels.
What this means practically for you
If you are taking a GLP-1 treatment and considering stopping, here are a few key points:
- Never stop without speaking to your doctor. The decision must be medically guided, taking your full cardiovascular profile into account.
- Benefits fade gradually after stopping. It is not immediate, but the study suggests that risk rises significantly within two years.
- Managing inflammation is not about medication alone. Adapted physical activity, sleep quality, stress management, and manual therapies all play a recognised complementary role.
The role of osteopathy in this context
Osteopathy is not a substitute for medication, and I would never claim otherwise. But it plays a valuable role in the broader management of chronic inflammation.
By working on tissue mobility, releasing joint and fascial restrictions, and regulating the autonomic nervous system, I help the body recover its own self-regulating capacity. Several of my patients on GLP-1 treatment for osteoarthritis have noticed a clear improvement in joint comfort by combining osteopathy with their medical treatment.
This complementarity between medicine and osteopathy is exactly what I aim to offer in Tel Aviv: an approach that does not choose between the two, but makes them work together.
The key takeaway
GLP-1 medications represent a genuine advance, and this new study reminds us that they should not be stopped lightly. But it also reminds us of something more fundamental: chronic inflammation is an ongoing process that requires ongoing attention.
Whether you are on medication or not, if you suffer from joint pain, stiffness, or persistent inflammation, an osteopathic consultation can help you better understand your body and support your long-term health.
If you would like to discuss this, I invite you to book an appointment at my practice in Tel Aviv. Together, we can build an approach tailored to your situation.
